| scholarly article | Q13442814 |
| P356 | DOI | 10.3233/JAD-150937 |
| P698 | PubMed publication ID | 26967213 |
| P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
| Peter Davies | Q42689763 | ||
| Jesus J Gomar | Q56993096 | ||
| P2093 | author name string | Terry E Goldberg | |
| Concepcion Conejero-Goldberg | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| “Mini-mental state” | Q25938989 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease | Q28610089 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| A data-driven model of biomarker changes in sporadic Alzheimer's disease | Q30835966 | ||
| Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration | Q33581412 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Structural MRI biomarkers for preclinical and mild Alzheimer's disease | Q34180987 | ||
| Primary age-related tauopathy (PART): a common pathology associated with human aging | Q34445021 | ||
| PART, a distinct tauopathy, different from classical sporadic Alzheimer disease | Q34467464 | ||
| Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry | Q34556945 | ||
| The evolution of preclinical Alzheimer's disease: implications for prevention trials | Q34849048 | ||
| Amyloid-β associated cortical thinning in clinically normal elderly | Q35053524 | ||
| Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study | Q35164302 | ||
| Emerging β-amyloid pathology and accelerated cortical atrophy | Q35542164 | ||
| Role of tau protein in both physiological and pathological conditions. | Q35715199 | ||
| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis | Q35800785 | ||
| Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis | Q35896890 | ||
| Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate | Q35902503 | ||
| Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease | Q35948528 | ||
| Amyloid-β associated volume loss occurs only in the presence of phospho-tau | Q36010484 | ||
| An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 | ||
| Soluble aβ promotes wild-type tau pathology in vivo | Q36650435 | ||
| Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 | ||
| Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts | Q37375828 | ||
| Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI | Q37419658 | ||
| Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 | ||
| Amyloid-independent mechanisms in Alzheimer's disease pathogenesis | Q37808579 | ||
| Animal models of Alzheimer disease | Q38045853 | ||
| Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease | Q41140682 | ||
| Aβ Oligomers Cause Localized Ca2+Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines | Q42913207 | ||
| Increasing CSF phospho-tau levels during cognitive decline and progression to dementia | Q48163038 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease | Q48410536 | ||
| Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years | Q48835886 | ||
| Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative | Q48916166 | ||
| The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. | Q53349838 | ||
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| cerebrospinal fluid | Q54196 | ||
| P304 | page(s) | 1085-1097 | |
| P577 | publication date | 2016-02-26 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease | |
| P478 | volume | 51 |
| Q64900616 | Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. |
| Q46187973 | Cerebral amyloid is associated with greater white-matter hyperintensity accrual in cognitively normal older adults |
| Q92465102 | Comments about SuperAging and SuperAgers |
| Q59843511 | Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals |
| Q41566620 | Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease |
| Q47324557 | Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. |
| Q90484535 | The impact of amyloid-beta and tau on prospective cognitive decline in older individuals |
Search more.